Abstract
Over time, the effective resistance mechanisms to various first-and second-line drugs against the disease of tuberculosis make its treatment extremely difficult. This work presents a new approach to synthesizing a hybrid of antituberculosis medications: isoniazid (INH) and pyrazinamide (PZA). The synthesis was performed using ultrasound-assisted synthesis to obtain an overall yield of 70%, minimizing the reaction time from 7 to 1 h. The evaluation of the biological activity of the hybrid (compound 2) was tested using the tetrazolium microplate assay (TEMA), showing inhibition in the growth of Mycobacterium tuberculosis H37Rv at a concentration of 0.025 mM at pH 6.0 and 6.7.
| Translated title of the contribution | Híbrido pirazinamida-isoniacida: optimización de síntesis, caracterización y actividad antituberculosa |
|---|---|
| Original language | English |
| Pages (from-to) | 16-23 |
| Number of pages | 8 |
| Journal | Revista Colombiana de Quimica |
| Volume | 50 |
| Issue number | 3 |
| DOIs | |
| State | Published - 2021 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- MIC
- isoniazid
- pyrazinamide
- tuberculosis TEMA
- ultrasound
Fingerprint
Dive into the research topics of 'Pyrazinamide–isoniazid hybrid: synthesis optimisation, characterisation, and antituberculous activity'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver